1 / 19

Clonal disorder Stable cytopenias for 2-6 weeks

Myelodysplastic disorders. Clonal disorder Stable cytopenias for 2-6 weeks Morphologic evidence of dysplastic changes in at least 2 hematopoietic cell lines Hypercellular or normocellular bone marrow Propensity to transform into AML in 20% of cases. Myelodysplastic disorders.

lorene
Télécharger la présentation

Clonal disorder Stable cytopenias for 2-6 weeks

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Myelodysplastic disorders • Clonal disorder • Stable cytopenias for 2-6 weeks • Morphologic evidence of dysplastic changes in at least 2 hematopoietic cell lines • Hypercellular or normocellular bone marrow • Propensity to transform into AML in 20% of cases

  2. Myelodysplastic disorders • Ineffective erythropoiesis due to increased apoptosis (programmed cell death) • Impaired cellular maturation due to intrinsic defects in cells of neoplastic clone • Altered responses to regulatory hormones

  3. Myelodysplastic disorders • Most over age 60 • Slight male predominance • History of acquired or congenital risk factors • radiation, chemotherapy (alkylating agents, topoisomerase inhibitors) • Hodgkin’s disease, non-Hodgkin’s lymphoma, multiple myeloma • ovarian CA, breast CA • NH3, diesel, benzene • aplastic anemia, paroxysmal nocturnal hemoglobinuria • Fanconi’s anemia, Down’s syndrome, Turner’s syndrome, Bloom’s syndrome

  4. Myelodysplastic disorders Red Cells • Macrocytosis • Low reticulocyte count • Ringed sideroblasts • Nuclear-cytoplasmic asynchrony • Bizarre nuclear configurations • Abnormal Fe metabolism

  5. Macrocytosis, biphenotypic population Ringed sideroblast Dysmorphic nucleated rbc’s Increased iron stores

  6. Myelodysplastic disorders White Cells • Hypogranulation • Nuclear-cytoplasmic asynchrony • Pseudo-Pelger-Huet anomaly • Defective adhesion, phagocytosis, and bacterial killing

  7. Hypogranulation, nuclear-cytoplasmic asynchrony Pseudo-Pelger-Huet anomaly Stodtmeister cell Aberrant granulation

  8. Myelodysplastic disorders Platelets • Giant, agranular platelets • Micromegakaryocytes and mononuclear megakaryocytes • Abnormal platelet function

  9. Hypogranular platelets Circulating micromegakaryocyte Abnormal megakaryocyte Mononuclear megakaryocyte

  10. Myelodysplastic disorders Other manifestations: • Rheumatologic - vasculitis, arthritis, lupus-like syndromes • Neurologic - peripheral neuropathy • Metabolic - abnormal LFT’s • Dermatologic - urticaria pigmentosa, chloroma, Sweet’s syndrome

  11. Chloroma Sweet’s Syndrome Granulocytic Sarcoma Extramedullary aggregates of blast cells Acute neutrophilic dermatosis Tender red plaques and nodules Benign infiltration of PMN’s in lower dermis

  12. Myelodysplastic disorders • C.M.L. • M.D.S. - five types: • Refractory Anaemia • Refractory Anaemia with ring sideroblasts • Refractory Anaemia with excess blasts • Refractory Anaemia with excess blasts in transformation • Chronic myelomonocytic leukaemia

  13. FAB Classification of MDS

  14. Supportive care of MDS • Supportive care • Hormonal and immunosuppressive therapy • Hematopoietic growth factors • Differentiating agents • Chemotherapy • Bone marrow transplantation

  15. Supportive care of MDS • RBC and platelet transfusions • Deferoxamine (Desferal) • Antibiotics • Avoidance of myelotoxic medications • Pyridoxine 200 mg QD

  16. Immunotherapy in MDS • Antithymocyte globulin +/- cyclosporine • Complete remissions in hypoplastic MDS • Eliminated transfusion requirement in 44% with normocellular and hypercellular MDS • Monoclonal antibody against CD33 • Disproportionately expressed on blast cells • Effective in those with <10% blasts

  17. Chemotherapy in MDS • Single agents • Low-dose cytarabine (LoDAC) • High-dose cytarabine (HiDAC) • Homoharringtonine • Topotecan • Combination therapy • Standard AML induction therapy • Fludarabine, cytarabine, idarubicin • Cyclophosphamide, cytarabine, topotecan

  18. Bone Marrow Transplantation in Myelodysplastic Syndrome Allogeneic BMT • Best results with • young patients (DFS 75%) • marrow blasts counts < 5% • absence of marrow fibrosis • interval to BMT < 5 years • matched sibling donor Treatment-related mortality 34-55% Disease-free survival 26-45% Relapse 19-34%

  19. Bone Marrow Transplantation in Myelodysplastic Syndrome Autologous BMT Higher relapse rate

More Related